A widely prescribed blood pressure drug was associated with a 33% higher risk of serious kidney problems in people with type 2 diabetes, even when they were already taking kidney-protective medications. The surprising finding is prompting researchers to question whether DCCBs are always the safest second-line choice for diabetic kidney disease.







